$ALDX News

HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target

Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow

Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease

Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter

Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally

Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript

BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease

Aldeyra Therapeutics to Host Regulatory Update Webcast

XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback

Aldeyra Therapeutics To Request FDA Type D Meeting On NDA Of Reproxalap Resubmission By End Of Q3 2026

Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL

CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock

Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors

Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment

Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Pleasing Signs As A Number Of Insiders Buy Aldeyra Therapeutics Stock

AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade)

What's Going On With Aldeyra Therapeutics Stock On Thursday?

Aspen’s fresh Parkinson’s data; Aldeyra tanks following FDA rejection